6 results match your criteria: ""Spirito Santo" Civic Hospital[Affiliation]"
Ceftolozane/Tazobactam and Ceftazidime/Avibactam: An Italian Multi-center Retrospective Analysis of Safety and Efficacy in Children With Hematologic Malignancies and Multi-drug Resistant Gram-negative Bacteria Infections.
Pediatr Infect Dis J
December 2022
Pediatric Hematology Oncology, Azienda Ospedaliera-Universitaria Integrata, Verona, Italy.
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia.
Blood Adv
March 2022
I.R.C.C.S., Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," Bologna, Italy.
Tyrosine kinase inhibitors have improved survival for patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). However, prognosis for old or unfit patients remains poor. In the INCB84344-201 (formerly GIMEMA LAL 1811) prospective, multicenter, phase 2 trial, we tested the efficacy and safety of ponatinib plus prednisone in newly diagnosed patients with Ph+ ALL ≥60 years, or unfit for intensive chemotherapy and stem cell transplantation.
View Article and Find Full Text PDFAutologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Lancet Haematol
June 2020
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Article Synopsis
- A clinical study was conducted to evaluate the effectiveness of autologous hematopoietic stem-cell transplantation (HSCT) versus the combination therapy of bortezomib-melphalan-prednisone (VMP) for newly diagnosed multiple myeloma patients.
- The research included untreated patients aged 18-65 with symptomatic multiple myeloma, enrolling at 172 centers within the European Myeloma Network and randomizing them to different treatment groups.
- After initial treatment with either VMP or HSCT, patients were randomized again to receive consolidation therapy with bortezomib-lenalidomide-dexamethasone or no consolidation, with the aim of assessing the overall benefits and outcomes of these treatment
Visceral leishmaniasis in relapsed and overtreated multiple myeloma in the era of high dose and "novel agent" therapy.
Int J Hematol
October 2015
Clinical Hematology, Department of Hematology, Transfusion Medicine and Biotechnology, "Spirito Santo" Civic Hospital, Pescara, Italy.
Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies.
Eur J Haematol
March 2009
Clinical Hematology, Department of Hematology, Spirito Santo Civic Hospital, Pescara, Italy.
Objectives: The therapy of advanced, relapsed or refractory primary cutaneous lymphomas is often unsatisfactory. Recent data indicate a favourable pharmacokynetic, pharmacodynamic and toxicity profile of pegylated liposomal doxorubicin (Peg-Doxo) in primary cutaneous T-cell lymphomas, while in primary cutaneous B-cell lymphomas (PCBCLs), the drug efficacy has never been assessed so far.
Methods: We performed a prospective phase II pilot clinical trial of Peg-Doxo monotherapy (20 mg/m(2)) in PCBCLs.
Hyperviscosity syndrome in hematological diseases and therapeutic apheresis.
Int J Artif Organs
October 2005
Department of Transfusion Medicine, Spirito Santo Civic Hospital, Pescara--Italy.
The hyperviscosity syndrome classified into pleiocytosic, sclerotic and sieric syndromes according to the blood components involved are characterized by a different degree of clinical signs and symptoms related to rheological modification of blood. Therapeutic management of these syndromes is complex and the choice of apheresis treatment is generally restricted to emergency episodes in order to overcome the acute phase and to reverse the symptoms until definitive therapy is effective.
View Article and Find Full Text PDF